SCHEMBL6176013

SCHEMBL6176013

CC(c1ccnc(NC(=O)c2ccc(F)cc2)c1)C1NC(=O)N(c2ccc(SC(F)(F)F)cc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 7/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
HTR1F P30939 2/20 0.40
KCNK2 O95069 2/20 0.38
MAPK14 Q16539 4/20 0.37
TRPV1 Q8NER1 1/20 0.35
PDE2A O00408 2/20 0.34
BUB1 O43683 1/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175275 0.94 IGF1R (0.41) IGF1RNPC1RAB9AKCNK2TRPV1
SCHEMBL6174760 0.93 IGF1R (0.41) IGF1RNPC1RAB9AKCNK2PDE2A
SCHEMBL6173765 0.91 KCNK2 (0.44) IGF1RNPC1RAB9AKCNK2MAPK14
SCHEMBL6177806 0.88 IGF1R (0.43) IGF1RPDE2A
SCHEMBL6174110 0.86 NPC1 (0.39) IGF1RNPC1RAB9AHTR1FMAPK14
SCHEMBL6175934 0.85 IGF1R (0.41) IGF1RNPC1RAB9A
SCHEMBL6177584 0.85 IGF1R (0.38) IGF1RKCNK2PDE2A
SCHEMBL6177171 0.84 IGF1R (0.46) IGF1RPDE2A
SCHEMBL6175915 0.84 IGF1R (0.42) IGF1RMAPK14PDE2A
SCHEMBL6173796 0.84 IGF1R (0.52) IGF1RPDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed